...
首页> 外文期刊>British Journal of Cancer >Changes in cellular glutathione content during adriamycin treatment in human ovarian cancer – a possible indicator of chemosensitivity
【24h】

Changes in cellular glutathione content during adriamycin treatment in human ovarian cancer – a possible indicator of chemosensitivity

机译:阿霉素治疗卵巢癌过程中细胞谷胱甘肽含量的变化-化学敏感性的可能指标

获取原文

摘要

Patients with ovarian cancer often respond well to combination chemotherapy initially but the majority eventually relapse when, with further treatment, the initially successful regimen proves ineffectual. The cause of such failures frequently has been attributed to the development of drug resistance. Although the mechanisms of acquired resistance in situ are still poorly understood, studies in vitro have shown that cells selected for resistance to one drug often exhibit cross-resistance to other seemingly unrelated agents, suggesting a somewhat generalised mechanism of resistance. We have studied the role of glutathione (GSH) and drug transport in determining the sensitivity to adriamycin (ADR) of a panel of human ovarian cell lines established directly from biopsies of patients with diverse treatment histories. These cell lines exhibited inherent differences in sensitivity to ADR by a dose factor of up to 3; a difference that was considerably less than what has been reported when cells were selected for drug resistance in vitro. The differences in drug sensitivity reported here among the various cell lines appeared to be unrelated to drug transport, in terms of both influx and efflux. Moreover, although these cell lines have a wide range of GSH content, there was only a poor correlation between drug sensitivity and cellular GSH content per se. However, when exposed to a clinically relevant dose of ADR, the GSH content of cell lines that were 'sensitive' decreased, whereas that of cell lines that were 'resistant' increased. To take these time-dependent changes in GSH into consideration, the area under the GSH content versus time curve (AUC), with and without ADR treatment, was calculated for each cell line. When this latter factor was included in the analysis, greatly improved correlations were found between GSH kinetic parameters and responses to ADR. In particular, ADR resistance was found to be closely correlated with the positive changes in absolute GSH AUC following ADR treatment (r = 0.92; P less than 0.01). Using 35S-labelled cysteine and methionine as tracers, it was found that the essential difference between the 'resistant' and 'sensitive' lines was that the 'resistant' lines had higher steady-state rates of GSH synthesis than the 'sensitive' lines. These results demonstrate that changes in cellular GSH concentration during treatment may be an important indicator of tumour cell response to ADR.
机译:卵巢癌患者通常最初对联合化疗反应良好,但是当进一步治疗后,最初成功的治疗方案证明无效,多数患者最终会复发。这种失败的原因经常归因于耐药性的发展。尽管对获得性原位耐药的机制仍知之甚少,但体外研究表明,被选为对一种药物具有抗性的细胞通常对其他看似无关的药物表现出交叉抗性,这表明某种程度上是普遍的抗性机制。我们已经研究了谷胱甘肽(GSH)和药物转运在确定直接根据具有不同治疗史的患者的活检建立的一组人类卵巢细胞系对阿霉素(ADR)的敏感性中的作用。这些细胞系对ADR的敏感性表现出固有的差异,最高可达3倍的剂量系数。这种差异远小于选择体外药物抗性细胞时所报道的差异。就流入和流出而言,这里报道的各种细胞系之间药物敏感性的差异似乎与药物转运无关。此外,尽管这些细胞系具有广泛的GSH含量,但药物敏感性与细胞GSH含量本身之间的相关性很差。但是,当暴露于临床上相关剂量的ADR时,“敏感”细胞系的GSH含量降低,而“耐药”细胞系的GSH含量升高。为了考虑到GSH的这些时间依赖性变化,针对每种细胞系,计算了经过和未经过ADR处理的GSH含量与时间曲线(AUC)下的面积。当将后一个因素包括在分析中时,发现GSH动力学参数与对ADR的反应之间的关联大大改善。特别是,发现ADR耐药性与ADR治疗后绝对GSH AUC的正变化密切相关(r = 0.92; P小于0.01)。使用35S标记的半胱氨酸和蛋氨酸作为示踪剂,发现“耐药”和“敏感”品系之间的本质区别在于,“耐药”品系比“敏感”品系具有更高的GSH合成稳态速率。这些结果表明,治疗期间细胞GSH浓度的变化可能是肿瘤细胞对ADR反应的重要指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号